Odefsey — Total revenues
Gilead Sciences Odefsey — Total revenues decreased by 28.9% to $221.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 21.4%, from $281.00M to $221.00M. Over 3 years (FY 2022 to FY 2025), Odefsey — Total revenues shows a downward trend with a -7.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market adoption or successful patient retention for this specific therapy, while a decrease may signal increased competition, patent expiration, or a shift in clinical treatment guidelines.
Detailed definition
This metric represents the total gross sales generated from a specific pharmaceutical product line within the company's...
Peer comparison
Comparable to product-level revenue reporting in other major biopharmaceutical companies, often benchmarked against similar therapeutic area franchises like HIV or oncology portfolios.
gild_segment_odefsey_total_revenuesHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $367.25M | $367.25M | $367.25M | $367.25M | $337.50M | $337.50M | $337.50M | $337.50M | $310.00M | $315.00M | $326.00M | $337.00M | $281.00M | $298.00M | $277.00M | $311.00M | $221.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -8.1% | +0.0% | +0.0% | +0.0% | -8.1% | +1.6% | +3.5% | +3.4% | -16.6% | +6.0% | -7.0% | +12.3% | -28.9% |
| YoY Change | — | — | — | — | -8.1% | -8.1% | -8.1% | -8.1% | -8.1% | -6.7% | -3.4% | -0.1% | -9.4% | -5.4% | -15.0% | -7.7% | -21.4% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's odefsey — total revenues?
- Gilead Sciences (GILD) reported odefsey — total revenues of $221.00M in Q1 2026.
- How has Gilead Sciences's odefsey — total revenues changed year-over-year?
- Gilead Sciences's odefsey — total revenues decreased by 21.4% year-over-year, from $281.00M to $221.00M.
- What is the long-term trend for Gilead Sciences's odefsey — total revenues?
- Over 3 years (2022 to 2025), Gilead Sciences's odefsey — total revenues has grown at a -7.4% compound annual growth rate (CAGR), from $1.47B to $1.17B.
- What does odefsey — total revenues mean?
- The total revenue generated by the sale of a specific HIV medication product line.